Floatz logo

Entecavir

Liver Fibrosis

Tanta UniversitySmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the Liver Fibrosis cohort.

Asset / SponsorPhaseRating
Peg-Intron
Beth Israel Deaconess Medical Center
Phase 4BB
COLCHICINUM
Zagazig University
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
Ribavirin
ANRS, Emerging Infectious Diseases
Phase 3BB
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB

View all 50 →

Same molecule, other indications

Entecavir is also rated in:

chronic hepatitis B virus infectionDormant
BBB
Indicative ·
74 / 100
View asset →
hepatitis B virus infectionDormant
BBB
Indicative ·
73 / 100
View asset →
non-Hodgkin lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →